|
Feb 24, 2010: THE SIESTA GROUP EXPANDS ITS RESEARCH ACTIVITIES AND
CLINICAL TRIALS BUSINESS
Vienna,
Austria
– The Siesta Group, creator of the
Somnolyzer 24x7 automated scoring technology, has sold its autoscoring
business
to Royal Philips Electronic and will focus its activities on
sleep-related
research and its clinical trial business.
The
reliable and valid measurement of sleep and, more
generally, cortical activity through EEG, is increasingly becoming a
central
concern in the development of CNS-active drugs, reaching much farther
than
drugs targeting sleep disorders alone. The market is in need for more
efficient
high quality solutions to deriving major sleep and EEG biomarkers, a
need that
is perfectly addressed by The Siesta Group’s technology.
While
Somnolyzer 24x7 is now property of Philips
Respironics being exploited in the diagnostic sleep center business,
The Siesta
Group remains the sole company making available this technology to the
benefit
of clinical trials worldwide.
Feb 24, 2010: PHILIPS STRENGTHENS SLEEP DIAGNOSTIC PORTFOLIO THROUGH
THE ACQUISITION OF AUTO-SCORING BUSINESS OF THE SIESTA GROUP IN AUSTRIA
Amsterdam,
The Netherlands and Vienna, Austria
– Royal Philips Electronics (AEX: PHI, NYSE:
PHG) announced today that it has acquired the Somnolyzer 24 x 7
automated scoring
solutions business of the Siesta Group in Vienna. This FDA-cleared
solution
will help improve the productivity of sleep centers and is based on the
most
advanced and clinically validated automated-scoring technology on the
market. The
Siesta Group is a research and clinical software company specializing
in polysomnography
scoring solutions
for sleep centers. The
acquired business will become part of the sleep diagnostics
business within Philips Home Healthcare
Solutions. Financial details of the agreement were not disclosed.
The
research and clinical trial services business, which are not part of
the
acquisition, will be retained and continue under the Siesta Group based
in Vienna.
For more
see here
(philips.com)
March 11, 2009 Worldwide sleep analysis leader The Siesta
Group celebrates FDA appoval for US go-to-market
This week’s FDA approval of
Somnolyzer 24x7 opens up the highly-valuable US sleep laboratory market to The
Siesta Group (TSG). TSG’s software package is set to boost existing
partnerships with top world med tech players.
TSG made a major milestone in its
worldwide go-to market strategy this week, after the US Food and Drug
Administration (FDA) approved its software package Somnolyzer
24x7®. The software is a
diagnostic aid for sleep and respiratory disorders.
Geriatric medicine and accident prevention initiatives are
just two main beneficiaries of the new possibilities opened up by TSG’s software.
Somnolyzer 24x7®, characterised by its
ease-of-use for health care personnel, evaluates established sleep
analysis parameters in accordance with the latest scientific research. This makes TSG a worldwide leader in computer
supported sleep analysis, and a prime partner for pharmaceutical and
other med-tech trials. Core markets include sleep labs scoring and
analysis, home diagnosis products and clinical trials, with a net worth
of €2.2bn.
TSG already has R&D
collaborations with academic groups, as well as with pioneering
sleep-medicine firms. The company, with a team of 13 European sleep
scientists and solid management, is now exploring other partnership
opportunities. It is backed by
lead-investor Gamma Capital Partners (GCP).
TSG CEO Dr Georg Dorffner was
enthusiastic that “thanks to the great efforts of our technical team
and the support by our consultant Boston Medtech Advisors, we received
the approval, which we need to make automated sleep analysis a new
standard in the delivery of care, in the shortest possible time, just
three months after our application. Patient satisfaction and treatment
outcome will improve, and the costs of sleep diagnosis will fall.”
GCP Partner Burkhard Feurstein
considered that “now could not be a better time for achievement in the US healthcare business. With a
major healthcare step-up planned by the new Obama Administration,
efficient yet cost-cutting products will be in high demand.”
Sleep is a fundamntal health
requirement, with growing evidence that a lack of sleep increases
susceptibility to cardiovascular diseases, obesity, or diabetes. An
average of 7-8 hours' sleep a night for adults is also essential for
optimum brain function and hormone regulation. The consequences of
sleep deprivation in professional life can be devastating; major
industrial accidents including the Chernobyl and Exxon Valdez fiascos
were cuased, in part, by overly-tired workers.
January 20, 2007 On Monday 14th of January 2007 The
Siesta Group was pleased to announce an expansion of the current
organization in Vienna, Austria in an effort to establish business
operations in North America.
The supervisory board met on Saturday January 12th and
approved the establishment of the North American operation. The
operation will begin sales activities immediately, and will seek to
expand further within the next 12 months with technical and
administrative resources to fully service the sleep diagnostic market.
The operation will be headed by Mr. Alexander Barr. (See Press Release
1/20/2007)
The emphasis of the initial entry into the North American
market will be complimented with the innovative automated sleep scoring
software, "Somnolyzer 24x7" an already clinically proven software tool
which is in current use throughout Europe and with significant effect
in the United States of America.
Somnolyzer 24x7 is a computer-based scoring tool that
tremendously increases a technician's efficiency in scoring
polysomnographic sleep studies. Its technology has been independently
proven to be among the world's leading scoring systems. The emphasis of
the product offering is found in 3 areas of Sleep Diagnostic Center
operations. i) Cost: Currently it is recognized nation wide that Sleep
Study costs are soaring for both labs and insurance providers.
Somnolyzer 24x7 in its nature significantly reduces the cost of
carrying out manual scoring activities and provides the lab more value
added activities expected from technical staff. ii) Consistency: By
reducing the variation currently evident in manual scoring the
consistent quality of scoring is maximized, aiding both technical
quality reviewers and physicians to depend on the results with
increased confidence, unmatched by any other system in the market. iii)
Cyber speed: With Somnolyzer 24x7, the speed at which sleep studies are
scored is increased with astounding prowess, resulting in sleep labs
becoming more efficient in managing scored studies into the hands of
Physicians, subsequently meaning that diagnosis and patient feedback is
also done in a more consistent and effective way.
The expansion of operations will mean that an infrastructure
will be in place to fully support the North American sleep diagnostic
centers from sales and technical support perspectives.
|
